Skip to main content

Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley

Tipranks - Tipranks - Wed Mar 4, 1:10AM CST

Morgan Stanley analyst Thibault Boutherin upgraded Novo Nordisk to a Hold today and set a price target of $40.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Boutherin is a 3-star analyst with an average return of 5.8% and a 53.13% success rate. Boutherin covers the Healthcare sector, focusing on stocks such as Novartis AG, Novo Nordisk, and Novo Nordisk.

The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a $51.17 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Novo Nordisk’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $78.43 billion and a net profit of $26.65 billion. In comparison, last year the company earned a revenue of $85.68 billion and had a net profit of $28.23 billion

Read More on NVO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).